Latest Lenalidomide Stories
Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON,
Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s
Unsealed federal lawsuit alleges that pharmaceutical giant engaged in unlawful marketing schemes involving blockbuster drugs Thalomid and Revlimid in cancer treatment, costing taxpayers hundreds of
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara
In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been
- A handkerchief.
- In general, any miraculous portrait of Christ.